(Total Views: 539)
Posted On: 10/27/2025 8:36:43 PM
Post# of 158792
Just read this blurb (boldface is mine) in an article titled "Guided missiles targeting tumor cells open a new route to combat cancer":
"And a new study presented this year at ESMO and published simultaneously in the prestigious New England Journal of Medicine (NEJM) has also shown that another of these new precision missiles, sacituzumab govitecan, is more effective than conventional chemotherapy in treating triple-negative breast cancer (the most aggressive type, affecting 15% of patients) in advanced stages: median progression-free survival was almost 10 months in those treated with this Trojan horse (in those treated with chemotherapy alone it was seven months)."
So, median progression free survival is "almost 10 months?"
It seems our guided missile might pack more punch than their guided missile.
And I know our study was small, but I think our tnbc results are worth at least a shout-out in the prestigious NEJM. Is the NEJM like the NASDAQ? Do we need a minimum market cap to get noticed?
"And a new study presented this year at ESMO and published simultaneously in the prestigious New England Journal of Medicine (NEJM) has also shown that another of these new precision missiles, sacituzumab govitecan, is more effective than conventional chemotherapy in treating triple-negative breast cancer (the most aggressive type, affecting 15% of patients) in advanced stages: median progression-free survival was almost 10 months in those treated with this Trojan horse (in those treated with chemotherapy alone it was seven months)."
So, median progression free survival is "almost 10 months?"
It seems our guided missile might pack more punch than their guided missile.
And I know our study was small, but I think our tnbc results are worth at least a shout-out in the prestigious NEJM. Is the NEJM like the NASDAQ? Do we need a minimum market cap to get noticed?
(13)
(0)
